Medication info
Dapagliflozin M Extended-Release Tablet 10/500 mg

Dapagliflozin M Extended-Release Tablet 10/500 mg

Prescription medicationTabletOral
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›15.27mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Samjin Pharmaceutical Co., Ltd.
Appearance
Pink, bilaterally convex, oval extended-release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 202301904 · Approved 2023.06.21 · Insurance code 647805640

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Ingredients

Manufacturer
Samjin Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors.
View approved original text

This medication is used to improve blood sugar control in adult patients with type 2 diabetes by combining dapagliflozin and metformin along with dietary and exercise therapy. Particularly, caution is necessary from medical professionals regarding the impact of dapagliflozin on the occurrence of cardiovascular events in type 2 diabetes patients who have insufficiently controlled blood sugar and have cardiovascular disease or risk factors. Therefore, this medication effectively assists in diabetes management and blood sugar control.

How to take

Adult dose

The dose of this medication should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medication is generally administered once daily with the evening meal. The maximum dose of this medication is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. For patients with no prior experience with antidiabetic drug therapy who have difficulty achieving adequate glycemic control with monotherapy: When used as initial therapy in patients with no prior experience with antidiabetic drug therapy, the recommended starting dose of this medication is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. In patients switching to this medication from combination therapy with dapagliflozin and metformin, this medication may be started at the doses of dapagliflozin and metformin the patient was previously receiving. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted as appropriate. The safety and efficacy of this medication have not been specifically evaluated in patients switching to it from another glucose-lowering medication. Because any change may cause a change in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medication whole; it must never be crushed, cut, or chewed. Occasionally, inactive ingredients in this medication may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, and no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medication, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medication is not recommended in patients with an eGFR below 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, this medication must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Because metformin is excreted by the kidneys and renal function is more likely to decline in older adults, this medication should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Section).

Precautions

This medication is used for treating diabetes and should not be administered to patients with reduced kidney function or certain health conditions. It may rarely cause a life-threatening metabolic complication known as lactic acidosis, so caution is required for patients with impaired kidney function or those experiencing severe infections, dehydration, etc. Also, when used in conjunction with insulin or sulfonylurea medications, the risk of hypoglycemia may increase, necessitating dosage adjustments. This medication may cause genital and urinary tract infections, and especially women or those with a history of infections should be vigilant about infection symptoms. Due to potential reduced fluid volume or symptoms of hypotension, elderly patients or those taking diuretics should regularly monitor their blood pressure and fluid status. This medication should not be used in patients with liver impairment, pregnant or nursing women, and those with lactose intolerance. It is advised to avoid alcohol while taking this medication, and if undergoing sudden surgery or contrast examinations, it should be temporarily discontinued. Blood levels of vitamin B12 may decrease, so regular blood tests are recommended for prolonged use. In case of overdose, immediate contact with a medical facility for proper treatment is essential, and while this medication has little influence on driving or machine operation, caution should be taken as dizziness may occur. Lastly, this medication should be kept out of reach of children and stored in its original container to prevent misuse or quality deterioration.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 86 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • pruritus of the vulva
  • pruritus of the genitals
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated blood creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • fever
  • burns
  • wrist fracture
  • gastrointestinal stromal tumors
  • malignant pulmonary neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • abnormal sensations
  • drowsiness
  • tremors
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • weakness
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasions
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipoproteinemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent exposure to air or moisture, ideally at room temperature between 1 degrees and 30 degrees. By storing this way, the medication's efficacy can be maintained and safely used.

Appearance and packaging

Appearance

Pink, bilaterally convex, oval extended-release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP*5)], 30 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.